Wright raises $550M; Wired takes on sleep wearables;

@FierceMedDev: Biosensors Japan's PhIII trial of drug eluting has enrolled patients. More | Follow @FierceMedDev

@VarunSaxena2: Check out these next-gen devices in the incubator pipeline: (Lots of pictures of new devices.) Report | Follow @VarunSaxena2

@EmilyWFierce: Pioneer in BRCA1 research once received a cease-and-desist letter from $MYGN's legal department. NYT story | Follow @EmilyWFierce

> Inundation by medical device alarms can lead to fatigue and overload for hospital staff. Here's one hospital that's working to reduce the aural stress on its healthcare providers from these alarms. Story

> Google ($GOOG) and Department of Defense-backed startup Wicab is seeking FDA approval to help the blind better perceive their surroundings. The Brainport device consists of a small video camera mounted to sunglasses that connects to a grid of 400 electrodes that send light electronic pulses to the tongue. Story

> Wired looks at next-gen sleep trackers that are effective enough to help to diagnose and treat sleep disorders. Story

> Wright Medical ($WMGI) has raised $550 million in debt to help finance its acquisition of Tornier. Release

> Medtronic ($MDT) reported 5-year data showing that its ClosureFast endovenous radiofrequency ablation catheter is safe and effective to treat chronic venous insufficiency. Release

Biotech News

@FierceBiotech: $MRK and $NVO join an open-source R&D club with $AMGN, $SNY and Ono. Report | Follow @FierceBiotech

@JohnCFierce: Game-changer: A new plan takes shape to spur the U.K.'s biotech cluster. More | Follow @JohnCFierce

@DamianFierce: Schleifer on PCSK9 launches: Initial splash w/ severe patients and "early adopters" followed by a 2nd boom when outcomes data come out $REGN. | Follow @DamianFierce

> Sarepta sees promising signs that antisense drug can guard against Ebola. Story

> Takeda says its 'breakthrough' cancer drug came through in Phase III. Article

> Report: Ex-Merck staffer working on insider-trading plea deal. Item

Pharma News

@FiercePharma: ICYMI yesterday: Serum Institute and Cipla in early merger talks. Story from FierceVaccines | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Daiichi's new clot-fighter Savaysa can't make up for $2.6B Benicar patent loss: analysts. Article | Follow @CarlyHFierce

> FDA puts off Mylan's Nexium generic, giving Teva's version free rein. More

> Showdown time for Amgen, Sandoz, with Neupogen biosim hearing set March 2. Article

Pharma Manufacturing News

> Cambrex ponies up $50M for another expansion of its Iowa API plant. News

> New Jersey company invests $1M in plant, now offers contract manufacturing. Article

> FDA letter takes issue with Micro Labs' data practices. Report

> China FDA orders respiratory API recalled after 'fur' like impurities found. Story

> Cipla to build a manufacturing plant in Morocco with local partners. Article

Biotech Research News

> UC Davis team finds a prime drug candidate for neuropathic pain. More

> Neuroscience project tries to put the immune system to work against Alzheimer's. Report

> Psychedelic drug shows promise as a new treatment for allergic asthma. Article

> Peptide could play a role in preventing binge eating, obesity. Item

> Antibody developed by NTU-led team in Singapore tracks flu recovery. Story

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.